Arvinas is redirecting resources to early-stage oncology and neurology programmes following FDA approval of VEPPANU, the first PROTAC degrader, which was licensed to Rigel Pharmaceuticals. The company's KRAS G12D programme, ARV-806, will only progress through a partner. Key clinical catalysts are expected for ARV-393 in lymphoma by year-end 2026, ARV-027 in spinal and bulbar muscular atrophy in the first half of 2027, and ARV-102 trials in neurodegenerative disease beginning in 2027. Arvinas reported $249.7 million in second-quarter revenue, including licence and milestone payments tied to VEPPANU. Cash and marketable securities totalled $567.9 million at 30 June, with management maintaining a cash runway into the second half of 2028.

Arvinas secured the first regulatory approval for a PROTAC protein degrader with VEPPANU and licensed it to Rigel Pharmaceuticals. The treatment is approved for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. The company expects to share clinical data from three Phase 1 programmes — ARV-393, ARV-102, and ARV-027 — over the next 12 months. Arvinas is initiating a Phase 1 trial for ARV-6723, an HPK1 degrader showing single-agent activity in preclinical models. The National Comprehensive Cancer Network added VEPPANU to its clinical practice guidelines for breast cancer as a Category 2A treatment option.

Arvinas reported second quarter 2026 financial results, highlighting VEPPANU's approval as the first-ever PROTAC protein degrader therapy and its subsequent out-licensing to Rigel Pharmaceuticals. The company plans to share clinical data from three Phase 1 programmes over the next 12 months. As of 30 June 2026, Arvinas held $567.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at year-end 2025. The company expects these funds to sustain operations into the second half of 2028. Second quarter revenue reached $249.7 million, compared with $22.4 million in the same period last year. The increase was primarily driven by recognition of deferred revenue from its Pfizer collaboration and $62.5 million from the Rigel licence agreement. Research and development expenses decreased to $52.6 million from $68.6 million year-over-year.